Yves Rinaldi

1.4k total citations
47 papers, 410 citations indexed

About

Yves Rinaldi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yves Rinaldi has authored 47 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 14 papers in Cancer Research. Recurrent topics in Yves Rinaldi's work include Colorectal Cancer Treatments and Studies (19 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer Treatment and Pharmacology (14 papers). Yves Rinaldi is often cited by papers focused on Colorectal Cancer Treatments and Studies (19 papers), Pancreatic and Hepatic Oncology Research (17 papers) and Cancer Treatment and Pharmacology (14 papers). Yves Rinaldi collaborates with scholars based in France, Austria and Canada. Yves Rinaldi's co-authors include Thomas Aparicio, F. Rétornaz, Laëtitia Dahan, Éric François, Karine Le Malicot, Jean‐Baptiste Bachet, Jean–Marc Phelip, Julien Taı̈eb, Olivier Bouché and Christophe Louvet and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Yves Rinaldi

41 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yves Rinaldi France	11	343	132	98	63	60	47	410
Robert Díaz Beveridge Spain	11	172 0.5×	139 1.1×	48 0.5×	63 1.0×	48 0.8×	43	317
Cédric Lecaille France	11	284 0.8×	143 1.1×	69 0.7×	123 2.0×	98 1.6×	21	449
Carlo Barone Italy	13	210 0.6×	200 1.5×	40 0.4×	66 1.0×	32 0.5×	20	394
Jeffrey T. Yorio United States	8	193 0.6×	136 1.0×	50 0.5×	70 1.1×	58 1.0×	22	323
Giuseppina Arcangeli Italy	7	227 0.7×	101 0.8×	27 0.3×	69 1.1×	58 1.0×	11	336
Julien Volet France	10	262 0.8×	119 0.9×	95 1.0×	109 1.7×	14 0.2×	23	361
E. Dotor Spain	10	270 0.8×	70 0.5×	154 1.6×	96 1.5×	67 1.1×	23	462
Giuseppe De Cataldis Italy	8	529 1.5×	518 3.9×	60 0.6×	49 0.8×	32 0.5×	14	708
Jacques Cretin France	7	171 0.5×	86 0.7×	48 0.5×	57 0.9×	41 0.7×	9	328
Helgi H. Helgason Netherlands	9	278 0.8×	149 1.1×	91 0.9×	31 0.5×	114 1.9×	21	449

Countries citing papers authored by Yves Rinaldi

Since Specialization

Citations

This map shows the geographic impact of Yves Rinaldi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Rinaldi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Rinaldi more than expected).

Fields of papers citing papers by Yves Rinaldi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Rinaldi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Rinaldi. The network helps show where Yves Rinaldi may publish in the future.

Co-authorship network of co-authors of Yves Rinaldi

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Rinaldi. A scholar is included among the top collaborators of Yves Rinaldi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Rinaldi. Yves Rinaldi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ducreux, Michel, Yves Rinaldi, Frédéric Di Fiore, et al.. (2025). PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology. 43(20). 2255–2264. 3 indexed citations

Assénat, Eric, Méher Ben Abdelghani, Sophie Gourgou, et al.. (2025). Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. Journal of Clinical Oncology. 43(23). 2616–2627. 1 indexed citations

Bouché, Olivier, Ahmet Ayav, Lilian Schwarz, et al.. (2024). LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44. Annals of Oncology. 35. S1252–S1252. 8 indexed citations

Rousseau, Benoı̂t, Thierry Lecomte, Aurélien Lambert, et al.. (2023). Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study.. Journal of Clinical Oncology. 41(4_suppl). 700–700. 1 indexed citations

Mazard, Thibault, François Ghiringhelli, Anke Winter, et al.. (2023). LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study. Annals of Oncology. 34. S1270–S1270. 2 indexed citations

Hilmi, Marc, Emmanuel Mitry, Anthony Turpin, et al.. (2022). A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.. Journal of Clinical Oncology. 40(16_suppl). 4148–4148. 3 indexed citations

Pietrasz, Daniel, Shufang Renault, Julien Taı̈eb, et al.. (2021). Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. British Journal of Cancer. 126(3). 440–448. 33 indexed citations

Dahan, Laëtitia, Nicolas Williet, Karine Le Malicot, et al.. (2021). Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Journal of Clinical Oncology. 39(29). 3242–3250. 45 indexed citations

Vanbrugghe, Charles, et al.. (2020). Robotic hepatic parenchymal transection: a two-surgeon technique using ultrasonic dissection and irrigated bipolar coagulation. Journal of Robotic Surgery. 15(4). 539–546. 11 indexed citations

10.

Guilbaud, Théophile, et al.. (2018). Cholangitis Due to Pancreaticobiliary Fistula and Intraductal Papillary Mucinous Neoplasm: Thick Mucus Alters the Effectiveness of BiliaryDrainage. JOP, journal of the pancreas. 19(4).

11.

Ducreux, Michel, Matthieu Texier, Frédéric Di Fiore, et al.. (2018). PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC). Annals of Oncology. 29. viii266–viii267. 3 indexed citations

12.

Rétornaz, F., Dany Gholam, F. Morvan, et al.. (2018). Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST (Massilia Oncologic Senior Tests) study.. Journal of Clinical Oncology. 36(15_suppl). 10041–10041. 1 indexed citations

13.

Aparicio, Thomas, Olivier Bouché, Julien Taı̈eb, et al.. (2017). Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results. Annals of Oncology. 29(1). 133–138. 50 indexed citations

14.

Lepage, Côme, Laurent Cany, E. Maillard, et al.. (2016). Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology. 27. vi159–vi159. 3 indexed citations

15.

Aparicio, Thomas, O. Bouché, Éric François, et al.. (2016). Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. Annals of Oncology. 27. vi194–vi194. 1 indexed citations

16.

Aparicio, Thomas, Olivier Bouché, Éric François, et al.. (2015). PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.. Journal of Clinical Oncology. 33(15_suppl). 3541–3541. 6 indexed citations

17.

Chibaudel, Benoist, Christophe Tournigand, Benoît Samson, et al.. (2014). Bevacizumab-Erlotinib As Maintenance Therapy in Metastatic Colorectal Cancer. Final Results of the Gercor Dream Study. Annals of Oncology. 25. iv167–iv167. 9 indexed citations

18.

Samson, Benoît, Christophe Tournigand, Werner Scheithauer, et al.. (2013). Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.. Journal of Clinical Oncology. 31(4_suppl). 448–448. 4 indexed citations

19.

Eisinger, François, et al.. (2010). Sociogeographical factors associated with participation in colorectal cancer screening. Gastroentérologie Clinique et Biologique. 34(10). 534–540. 15 indexed citations

20.

Tifratène, Karim, et al.. (2007). Colorectal cancer screening program: cost effectiveness of systematic recall letters. Gastroentérologie Clinique et Biologique. 31(11). 929–933. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact